Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

PYXS Pyxis Oncology Inc

Price (delayed)

$1.28

Market cap

$79.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.58

Enterprise value

$84.9M

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype ...

Highlights
Pyxis Oncology's debt has decreased by 4.5% YoY
PYXS's quick ratio is down by 37% year-on-year but it is up by 2.1% since the previous quarter
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY
Pyxis Oncology's gross profit has shrunk by 100% QoQ and by 100% YoY

Key stats

What are the main financial stats of PYXS
Market
Shares outstanding
61.95M
Market cap
$79.29M
Enterprise value
$84.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$106.77M
Net income
-$95.23M
EBIT
-$97.4M
EBITDA
-$94.25M
Free cash flow
-$59.5M
Per share
EPS
-$1.58
EPS diluted
-$1.58
Free cash flow per share
-$0.97
Book value per share
$1.67
Revenue per share
$0
TBVPS
$2.18
Balance sheet
Total assets
$135.87M
Total liabilities
$32.76M
Debt
$19.84M
Equity
$103.1M
Working capital
$97.44M
Liquidity
Debt to equity
0.19
Current ratio
7.75
Quick ratio
7.41
Net debt/EBITDA
-0.06
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-54.7%
Return on equity
-69.6%
Return on invested capital
-67%
Return on capital employed
-80.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PYXS stock price

How has the Pyxis Oncology stock price performed over time
Intraday
-3.03%
1 week
6.67%
1 month
1.59%
1 year
-64.93%
YTD
-17.95%
QTD
30.63%

Financial performance

How have Pyxis Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$106.77M
Net income
-$95.23M
Gross margin
N/A
Net margin
N/A
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY
Pyxis Oncology's gross profit has shrunk by 100% QoQ and by 100% YoY
Pyxis Oncology's net income has shrunk by 65% YoY and by 23% QoQ
The operating income has plunged by 60% YoY and by 19% from the previous quarter

Price vs fundamentals

How does PYXS's price correlate with its fundamentals

Growth

What is Pyxis Oncology's growth rate over time

Valuation

What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PYXS's EPS is down by 20% since the previous quarter and by 16% year-on-year
The equity has contracted by 44% YoY and by 15% from the previous quarter
PYXS's P/B is 24% below its last 4 quarters average of 1.0
Pyxis Oncology's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Pyxis Oncology business performance
Pyxis Oncology's ROA has plunged by 79% YoY and by 38% from the previous quarter
The return on equity has dropped by 78% year-on-year and by 41% since the previous quarter
The ROIC has plunged by 76% YoY and by 33% from the previous quarter

Dividends

What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PYXS.

Financial health

How did Pyxis Oncology financials performed over time
The company's total assets fell by 38% YoY and by 14% QoQ
PYXS's quick ratio is down by 37% year-on-year but it is up by 2.1% since the previous quarter
Pyxis Oncology's debt is 81% lower than its equity
The debt to equity has surged by 73% year-on-year and by 12% since the previous quarter
The equity has contracted by 44% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.